BRIDGEWATER, New Jersey, 26 févr. 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (« Synchronoss » ou la « Société ») (NASDAQ : SNCR), un innovateur et leader mondial des plateformes de cloud personnel, organisera une conférence téléphonique le mardi 11 mars 2025 à 16 h 30, heure de l’Est (13 h 30, heure du Pacifique) pour faire le point sur ses résultats financiers du quatrième trimestre et sur […]
Africa
Mavenir and OXIO Powering the Next Generation of MVNOs
OXIO’s Telecom-as-a-Service Platform integrates Mavenir Packet Core, IMS and Messaging solutions on Amazon Web Services for enhanced agility RICHARDSON, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network infrastructure provider building the future of networks, today announced that it has been selected by OXIO, a leading Telecom-as-a-Service (TaaS) company, for Packet Core, IMS […]
Mavenir and OXIO Powering the Next Generation of MVNOs
OXIO’s Telecom-as-a-Service Platform integrates Mavenir Packet Core, IMS and Messaging solutions on Amazon Web Services for enhanced agility RICHARDSON, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network infrastructure provider building the future of networks, today announced that it has been selected by OXIO, a leading Telecom-as-a-Service (TaaS) company, for Packet Core, IMS […]
Mavenir and O2 Telefónica Germany Strengthen Partnership with Multi-Year IMS Contract Extension for Cloud-Native IMS Services
New five-year contract with Mavenir powering O2 Telefónica to transition its 4G/5G voice services to latest cloud-native technology MUNICH and BONN, Germany, Feb. 26, 2025 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that it has strengthened its long-term partnership with Telefónica and its global operating companies, […]
IAVI and Biofabri/Zendal Announce First Vaccinations in the IMAGINE Clinical Trial, a Large-scale Safety and Efficacy Trial of the Tuberculosis Vaccine Candidate MTBVAC
Tuberculosis (TB) is the world’s deadliest infectious disease, killing 1.25 million people in 2023.MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial, a large-scale safety and efficacy trial evaluating the prevention of TB dis…